1 / 7

Spinal Muscular Atrophy Therapeutics – Pipeline Analysis, Clinical Trials & Results

Spinal Muscular Atrophy (SMA) Therapeutics Pipeline, Market Analysis and Forecast for the Drug Candidates in the Latest Stage of Development.

NidhiNehani
Download Presentation

Spinal Muscular Atrophy Therapeutics – Pipeline Analysis, Clinical Trials & Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Spinal Muscular Atrophy Therapeutics Pipeline to Receive More R&D Investments in the Future

  2. Spinal Muscular Atrophy (SMA) According to a new research report “Spinal Muscular Atrophy Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, spinal muscular atrophy currently exhibits a pipeline with 16 drug candidates. Browse Report Description at: https://www.psmarketresearch.com/market-analysis/spinal-muscular-atrophy-therapeutics-pipeline-analysis

  3. Spinal Muscular Atrophy (SMA) Spinal muscular atrophy therapeutics pipeline in 2017 The study analyzed that the therapeutics pipeline comprises approximately 16 drug candidates in different stages of development. Spinal muscular atrophy is defined as the inherited genetic disease that is characterized by a failure of nerve cells called motor neurons. Motor neurons are responsible to accept the nerve impulses transmitted from the brain to the spinal cord and transmit the impulses to the muscle with the help of peripheral nerves. The loss of motor neurons leads to muscle weakness in muscles that are closest to the trunk of the body such as back, hips and shoulders.

  4. Spinal Muscular Atrophy (SMA) Nucleic acid therapeutics technology platform for spinal muscular atrophy drug development Imago Pharmaceuticals, Inc. is using nucleic acid therapeutics technology platform for the treatment of spinal muscular atrophy. Nucleic acid therapeutics technology includes large and innovative class of drugs that can modulate the function of target ribonucleic acid, or RNA, to ultimately affect the production of disease-associated proteins. Nucleic acid therapeutics comprise of complex mixtures of various chemical entities known as stereoisomers. Some stereoisomers in these mixtures have therapeutic effects, while others are less beneficial or contribute to undesirable side effects. Uncontrolled stereoisomer drug mixtures can lead to suboptimal efficacy and increased risk and safety concerns.

  5. Spinal Muscular Atrophy (SMA) Synthetic Sources are being used for the development of drugs The research also found that there are several companies that use synthetic sources for the development of drugs for the treatment of spinal muscular atrophy. Some of the other key players developing drugs for the treatment of spinal muscular atrophy include Cytokinetics, Inc., F. Hoffman La-Roche Ltd, WAVE Life Sciences Ltd. and others.

  6. Spinal Muscular Atrophy (SMA) Download report sample at: https://www.psmarketresearch.com/market-analysis/spinal-muscular-atrophy-therapeutics-pipeline-analysis/report-sample

  7. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related